LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Antibodies Isolated from Ebola Survivors Recognize Wide Range of Ebolavirus Species

By LabMedica International staff writers
Posted on 01 Feb 2016
Print article
Image: Under very-high magnification, this digitally-colorized scanning electron micrograph (SEM) depicts a number of filamentous Ebolavirus particles (red) that had budded from the surface of a VERO cell (brown) of the African green monkey kidney epithelial cell line (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).
Image: Under very-high magnification, this digitally-colorized scanning electron micrograph (SEM) depicts a number of filamentous Ebolavirus particles (red) that had budded from the surface of a VERO cell (brown) of the African green monkey kidney epithelial cell line (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).
A team of molecular virologists has isolated human monoclonal antibodies from Ebola survivors that were able to neutralize multiple species of the virus and protect guinea pigs from challenge with the live virus.

Recent studies had suggested that antibody-mediated protection against the Ebolaviruses might be achievable, but little was known about whether or not antibodies could confer cross-reactive protection against viruses belonging to diverse Ebolavirus (EBOV) species, such as Sudan ebolavirus (SUDV) and Bundibugyo ebolavirus (BDBV).

To clarify this point investigators at Vanderbilt University (Nashville, TN, USA) and the University of Texas Medical Branch (Galveston, USA) isolated a large panel of human monoclonal antibodies (mAbs) against BDBV glycoprotein (GP) using peripheral blood B cells from survivors of the 2007 BDBV outbreak in Uganda.

The investigators reported in the January 21, 2016, online edition of the journal Cell that a large proportion of mAbs with potent neutralizing activity against BDBV bound to the viral glycan cap and recognized diverse epitopes within this major antigenic site. They identified several glycan cap-specific mAbs that neutralized multiple ebolaviruses, including SUDV, and a cross-reactive mAb that completely protected guinea pigs from lethal challenge with heterologous EBOV.

"We thought we would need five different sets of vaccines or five different (drugs)," said senior author Dr. James Crowe Jr., professor of pediatrics, pathology, microbiology, and immunology at Vanderbilt University. "This work suggests there are common elements across different groups of Ebola viruses. Maybe we can come up with one therapeutic or one vaccine that would solve all of them. This work points the way to using fully human antibodies as the next generation of antibody therapeutics. From the human antibody work [...] and the vaccine work that is being done, it is clear we can find a protective strategy for Ebola. That is a big step forward."

Related Links:

Vanderbilt University
University of Texas Medical Branch


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more